Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ovid Makes Two New Appointments

This article was originally published in Scrip

Executive Summary

Ovid Therapeutics has appointed Amit Rakhit chief medical and portfolio management officer and Daniel H. Geschwind to the company's scientific advisory board. Prior to Ovid, Rakhit was senior vice president, head of worldwide medical at Biogen and he was also vice president, program leadership and management at Biogen. Previously he held leadership roles at Bristol-Myers Squibb including director, cardiovascular R&D and executive medical director, cardiovascular/metabolics. Recently Geschwind was appointed senior associate dean and associate vice chancellor of precision medicine in the UCLA Health System and David Geffen School of Medicine. He is a professor of neurology and psychiatry and biobehavioral sciences at the UCLA School of Medicine and director of the Center for Autism Research and Treatment (CART) and co-director of the center for neurobehavioral genetics at UCLA.

You may also be interested in...

Text Mining And Machine Reading: The Answer To Pharma's R&D Data Mountain?

How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.

Adherence Issues Add Weight To Digital Trials Push

Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.

Appointments: Five Prime, Depomed, Gilead, Arix Bioscience and Corbus

This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts